Quaratusugene ozeplasmid clinical trials
How each study uses quaratusugene ozeplasmid has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the quaratusugene ozeplasmid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Genprex, Inc. (3)
Studies
Open first, then newest update. How each study uses quaratusugene ozeplasmid has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingPhase 1/2Genprex, Inc.NCT04486833Written as quaratusugene ozeplasmidHow we knowReport a problem
- Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsRecruitingPhase 1/2Genprex, Inc.NCT05703971Written as quaratusugene ozeplasmidHow we knowReport a problem
- Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedPhase 1Genprex, Inc.NCT05062980Written as quaratusugene ozeplasmidHow we knowReport a problem
Tested with established drugs · 3 — they are given beside it
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingPhase 1/2Genprex, Inc.NCT04486833Written as quaratusugene ozeplasmidHow we knowReport a problem
- Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsRecruitingPhase 1/2Genprex, Inc.NCT05703971Written as quaratusugene ozeplasmidHow we knowReport a problem
- Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedPhase 1Genprex, Inc.NCT05062980Written as quaratusugene ozeplasmidHow we knowReport a problem
Codes
What other systems call quaratusugene ozeplasmid · ClinicalTrials.gg INT017168
- UNII (FDA) LD93JWY9D9QUARATUSUGENE OZEPLASMIDOne source FDA
- NCI Thesaurus C91708Quaratusugene OzeplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LD93JWY9D9 | QUARATUSUGENE OZEPLASMID | One source FDA |
| NCI Thesaurus | C91708 | Quaratusugene Ozeplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.